Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 15/20 | 0.42 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4510509 | 0.92 | PDE4B (0.45) | PDE4BPDE7APIK3CDPIK3R1PIK3CA | |
| SCHEMBL4511362 | 0.89 | PDE4B (0.43) | PDE4BPDE7APIK3CDPIK3R1PIK3CA | |
| Trifluoroacetic Acid SCHEMBL4526719 | 0.89 | PDE4B (0.41) | PDE4BPDE7APIK3CDPIK3R1PIK3CA | |
| SCHEMBL4531325 | 0.89 | PDE4B (0.42) | PDE4BPDE7APIK3CDPIK3R1PIK3CA | |
| SCHEMBL4520844 | 0.87 | PDE4B (0.52) | PDE4BPDE7A | |
| SCHEMBL4519387 | 0.87 | PDE4B (0.44) | PDE4BPDE7APIK3CDPIK3R1PIK3CA | |
| SCHEMBL4507091 | 0.87 | PDE4B (0.41) | PDE4BPDE7APIK3CDPIK3R1PIK3CA | |
| SCHEMBL4520179 | 0.87 | PDE4B (0.44) | PDE4BPDE7APDE4D | |
| Trifluoroacetic Acid SCHEMBL4520452 | 0.86 | PDE4B (0.39) | PDE4BPDE7APIK3CDPIK3R1PIK3CA | |
| SCHEMBL4518989 | 0.86 | PDE4B (0.43) | PDE4BPDE7APIK3CDPIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090326003-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-12-31 | — | — | US | claimed |
| US-20090326003-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326003-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE12 | PDE4B 2/4885PDE7A 10/4885PIK3CD 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.